Skip to Content

Octreotide Injection

Last Updated: April 2, 2018
Status: Current

Octreotide Injection

Products Affected - Description
  • Octreotide Acetate injection, Fresenius Kabi
    50 mcg/mL, 1 mL vial, 10 count (NDC 63323-0365-01)

 
Octreotide Acetate injection, Sagent
1000 mcg/mL, 5 mL vial, 1 count (NDC 25021-0455-05)
 
Octreotide Acetate injection, Sun Pharma
50 mcg/mL, 1 mL ampule, 10 count (NDC 62756-0348-44)
100 mcg/mL, 1 mL ampule, 10 count (NDC 62756-0349-44)
200 mcg/mL, 5 mL vial, 1 count (NDC 62756-0350-40)
500 mcg/mL, 1 mL ampule, 10 count (NDC 62756-0351-44)
1000 mcg/mL, 5 mL vial, 1 count (NDC 62756-0352-40)
Reason for the Shortage
    • Fresenius Kabi has octreotide available.
    • Mylan Institutional has octreotide available.
    • Sagent has octreotide on shortage due to manufacturing delays.
    • Sun Pharma did not provide a reason for the shortage.
    • Teva has octreotide available.
    • Novartis has Sandostatin available.
    • West-Ward has octreotide available.
Available Products
  • Sandostatin injection, Novartis
    50 mcg/mL, 1 mL ampule, 10 count (NDC 00078-0180-01)

100 mcg/mL, 1 mL ampule, 10 count (NDC 00078-0181-01)
200 mcg/mL, 5 mL vial, 1 count (NDC 00078-0183-25)
500 mcg/mL, 1 mL ampule, 10 count (NDC 00078-0182-01)
1000 mcg/mL, 5 mL vial, 1 count (NDC 00078-0184-25)
 
Octreotide Acetate injection, Fresenius Kabi
100 mcg/mL, 1 mL vial, 10 count (NDC 63323-0376-01)
200 mcg/mL, 5 mL vial, 1 count (NDC 63323-0378-05)
500 mcg/mL, 1 mL vial, 10 count (NDC 63323-0377-01)
1000 mcg/mL, 5 mL vial, 1 count (NDC 63323-0379-05)
 
Octreotide Acetate injection, Mylan Institutional
50 mcg/mL, 1 mL syringe, 10 count (NDC 67457-0239-01)
100 mcg/mL, 1 mL syringe, 10 count (NDC 67457-0245-01)
500 mcg/mL, 1 mL syringe, 10 count (NDC 67457-0246-01)
 
Octreotide Acetate injection, Sagent
50 mcg/mL, 1 mL vial, 10 count (NDC 25021-0451-01)
100 mcg/mL, 1 mL vial, 10 count (NDC 25021-0452-01)
200 mcg/mL, 5 mL vial, 1 count (NDC 25021-0454-05)
500 mcg/mL, 1 mL vial, 10 count (NDC 25021-0453-01)
 
Octreotide Acetate injection, Teva
50 mcg/mL, 1 mL vial, 25 count (NDC 00703-3301-04)
100 mcg/mL, 1 mL vial, 25 count (NDC 00703-3311-04)
200 mcg/mL, 5 mL vial, 1 count (NDC 00703-3333-01)
500 mcg/mL, 1 mL vial, 25 count (NDC 00703-3321-04)
1000 mcg/mL, 5 mL vial, 1 count (NDC 00703-3343-01)
 
Octreotide Acetate injection, West-Ward
50 mcg/mL, 1 mL vial, 10 count (NDC 00641-6174-10)
100 mcg/mL, 1 mL vial, 10 count (NDC 00641-6175-10)
200 mcg/mL, 5 mL multiple dose vial, 1 count (NDC 00641-6177-10)
500 mcg/mL, 1 mL vial, 10 count (NDC 00641-6176-10)
1,000 mcg/mL, 5 mL multiple dose vial, 1 count (NDC 00641-6178-10)

Estimated Resupply Dates

    • Fresenius Kabi has octreotide 50 mcg/mL 1 mL vials on back order and the company estimates a release date of 2nd quarter 2018.
    • Sagent has octreotide 1,000 mcg/mL 5 mL vials on back order and the company estimates a release date of April 2018.
    • Sun Pharma has all octreotide presentations on back order and the company cannot estimate a release date.

Updated

April 2, March 9, February 22, 10 and 6, January 24, 2018; December 7, October 25 and 5, September 20, August 10, July 7, June 14, May 5, April 4, March 24, 21 and 13, February 21, January 6, 2017; December 9, November 21 and 10, October 5, August 25, 18 and 5, July 14, June 28, May 27, 20 and 17, April 14 and 13, March 16, 2016, University of Utah, Drug Information Service. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.

Hide